Sigma Life Science, the biological products and services research business of Sigma-Aldrich, announced that its SAGE Labs initiative has created a suite of knockout rat models of Parkinson’s disease in collaboration with The Michael J Fox Foundation for Parkinson’s Research (MJFF). Developed using the proprietary SAGEspeed model creation process, these off-the-shelf rat models represent a breakthrough in Parkinson’s disease research, overcoming the inherent limitations of the existing mouse models.
Knockout rat models offer significant advantages over the existing mouse models, which do not effectively mimic the symptoms of Parkinson’s disease in humans. The neuronal circuitry of the rat model more closely imitates that of humans, better demonstrating the disease symptoms, and rats’ size and behaviour allow researchers to perform a variety of experimental procedures more easily than in mice. In collaboration with MJFF, SAGE Labs has used Sigma Life Science’s CompoZr Zinc Finger Nuclease (ZFN) technology to create a range of knockout rat models specific to Parkinson’s disease, based on existing knowledge of the key genes implicated in the disease. This groundbreaking collection of rat models currently includes LRRK2, Parkin, Pink1 and DJ-1 knockouts which will help researchers accelerate investigation of novel therapeutic strategies for Parkinson’s disease.
“This collaboration with The Michael J Fox Foundation for Parkinson’s Research highlights the enormous potential of our CompoZr and SAGEspeed technology platforms, and displays our commitment to providing the scientific community with tools for cutting-edge research into diseases that afflict the human population,” said Dr Edward Weinstein, Director of SAGE Labs at Sigma Life Science.
Sigma-Aldrich
Showing posts with label Sigma Life Science. Show all posts
Showing posts with label Sigma Life Science. Show all posts
Friday, 18 March 2011
Thursday, 17 March 2011
Sigma Life Science launches suite of knockout rats to model Parkinson’s disease
Sigma Life Science, the biological products and services research business of Sigma-Aldrich, announced that its SAGE Labs initiative has created a suite of knockout rat models of Parkinson’s disease in collaboration with The Michael J Fox Foundation for Parkinson’s Research (MJFF). Developed using the proprietary SAGEspeed model creation process, these off-the-shelf rat models represent a breakthrough in Parkinson’s disease research, overcoming the inherent limitations of the existing mouse models.
Knockout rat models offer significant advantages over the existing mouse models, which do not effectively mimic the symptoms of Parkinson’s disease in humans. The neuronal circuitry of the rat model more closely imitates that of humans, better demonstrating the disease symptoms, and rats’ size and behaviour allow researchers to perform a variety of experimental procedures more easily than in mice. In collaboration with MJFF, SAGE Labs has used Sigma Life Science’s CompoZr Zinc Finger Nuclease (ZFN) technology to create a range of knockout rat models specific to Parkinson’s disease, based on existing knowledge of the key genes implicated in the disease. This groundbreaking collection of rat models currently includes LRRK2, Parkin, Pink1 and DJ-1 knockouts which will help researchers accelerate investigation of novel therapeutic strategies for Parkinson’s disease.
“This collaboration with The Michael J Fox Foundation for Parkinson’s Research highlights the enormous potential of our CompoZr and SAGEspeed technology platforms, and displays our commitment to providing the scientific community with tools for cutting-edge research into diseases that afflict the human population,” said Dr Edward Weinstein, Director of SAGE Labs at Sigma Life Science.
Sigma-Aldrich
Knockout rat models offer significant advantages over the existing mouse models, which do not effectively mimic the symptoms of Parkinson’s disease in humans. The neuronal circuitry of the rat model more closely imitates that of humans, better demonstrating the disease symptoms, and rats’ size and behaviour allow researchers to perform a variety of experimental procedures more easily than in mice. In collaboration with MJFF, SAGE Labs has used Sigma Life Science’s CompoZr Zinc Finger Nuclease (ZFN) technology to create a range of knockout rat models specific to Parkinson’s disease, based on existing knowledge of the key genes implicated in the disease. This groundbreaking collection of rat models currently includes LRRK2, Parkin, Pink1 and DJ-1 knockouts which will help researchers accelerate investigation of novel therapeutic strategies for Parkinson’s disease.
“This collaboration with The Michael J Fox Foundation for Parkinson’s Research highlights the enormous potential of our CompoZr and SAGEspeed technology platforms, and displays our commitment to providing the scientific community with tools for cutting-edge research into diseases that afflict the human population,” said Dr Edward Weinstein, Director of SAGE Labs at Sigma Life Science.
Sigma-Aldrich
Thursday, 10 March 2011
Sigma adds 1,400 cell lines to its US portfolio of ECACC products
Sigma Life Science, the biological products and services business of Sigma-Aldrich, has announced the addition of 1,400 new European Collection of Cell Culture (ECACC) cell lines to its collection of cell line cultures and services. These cell lines have been fully authenticated and tested free of mycoplasma and can now be delivered within days to customers in the U.S., Mexico and Canada. ECACC is a recognized worldwide expert in the maintenance, cultivation and distribution of authenticated cell lines. The collection of cell lines can be accessed at www.sigma.com/ecacc.
Scientists rely upon these cell lines, which include human, mouse and insect, for cell-based assays that determine the safety and efficacy of drug candidates. Due to high costs and the great amount of time required for research and development, drug developers prefer to use cell-based assays in cell signaling studies, cancer research and other areas in order to correct issues that may arise, as early as possible, in the research cycle.
“This is an exciting development for the research community,” said Dr Bryan Bolton, Commercial Manager at ECACC. “Sigma Life Science can now provide North American scientists with the benefits of ready access to a complete collection of original ECACC manufactured cell lines, which are fully authenticated using the latest DNA profiling techniques.”
Don Finley, Market Segment Manager of Research Cell Culture at Sigma Life Science, said: “We can now serve the global scientific community with a broader range of more easily available ECACC cell lines. In light of increased interest in cell based research, our plan is to offer an exhaustive collection of high quality cell lines to meet needs of our customers for cell based solutions."
Scientists rely upon these cell lines, which include human, mouse and insect, for cell-based assays that determine the safety and efficacy of drug candidates. Due to high costs and the great amount of time required for research and development, drug developers prefer to use cell-based assays in cell signaling studies, cancer research and other areas in order to correct issues that may arise, as early as possible, in the research cycle.
“This is an exciting development for the research community,” said Dr Bryan Bolton, Commercial Manager at ECACC. “Sigma Life Science can now provide North American scientists with the benefits of ready access to a complete collection of original ECACC manufactured cell lines, which are fully authenticated using the latest DNA profiling techniques.”
Don Finley, Market Segment Manager of Research Cell Culture at Sigma Life Science, said: “We can now serve the global scientific community with a broader range of more easily available ECACC cell lines. In light of increased interest in cell based research, our plan is to offer an exhaustive collection of high quality cell lines to meet needs of our customers for cell based solutions."
Monday, 21 February 2011
Oncology disease model cell lines
Sigma Life Science, the biological products and services research business of Sigma-Aldrich, today announced the addition of new genetically modified cancer cells to the company’s range of high-quality cell lines. These human knockout and knock-in oncology cell lines, created using Sigma’s proprietary CompoZr Zinc Finger Nuclease (ZFN) technology which received a silver medal as a Top Ten Innovations of 2010 from The Scientist magazine, offer researchers cellular models of cancer that are expected to enhance development of drugs for personalized medicine.
Wednesday, 2 February 2011
Free public database of exclusive genomic information
Sigma Life Science, the biological products and services business of Sigma-Aldrich, today announced that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. As part of the agreement, Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at sageresearchmodels.com in late 2011. The database will include exclusive genomic information and analysis tools.
Monday, 13 December 2010
Knock-in rats using zinc finger nuclease technology
Sigma Life Science, the biological products and services business of Sigma-Aldrich, today announced that its SAGE Labs initiative has successfully used its proprietary CompoZr Zinc Finger Nuclease (ZFN) technology to generate knock-in rats in which foreign genes have been inserted, or ‘knocked-in’, into the rat genome in a precisely targeted manner. This breakthrough achievement represents a major step forward in the creation of a transgenic animal, which may serve as more predictive models of human disease.
In a proof of concept study conducted by researchers at SAGE Labs, a copy of the green fluorescent protein (GFP) was inserted in a targeted fashion into the Mdr1a gene of a rat, thus creating a rat that glows under special lighting conditions. The study, which has recently been accepted for publication1, opens the doors to a variety of new applications including the tagging of genes with reporters such as GFP to measure gene expression patterns and replacement of rat genes with humanized versions.
In a proof of concept study conducted by researchers at SAGE Labs, a copy of the green fluorescent protein (GFP) was inserted in a targeted fashion into the Mdr1a gene of a rat, thus creating a rat that glows under special lighting conditions. The study, which has recently been accepted for publication1, opens the doors to a variety of new applications including the tagging of genes with reporters such as GFP to measure gene expression patterns and replacement of rat genes with humanized versions.
Monday, 22 November 2010
Sigma Life Science collection of Prestige Antibodies exceeds 10,000
As the industry’s most highly validated antibodies, each Prestige Antibody is supported by over 700 immunohistochemistry, immunofluorescence and Western blot images, with complete data for each product publicly available through the Human Protein Atlas. The continued expansion of this collection is part of the Swedish Human Proteome Resource (HPR) program to develop at least one antibody to all non-redundant human proteins by 2015.
Thursday, 4 November 2010
Distribution of mouse models to the scientific community
Sigma Life Science and The Jackson Laboratory (JAX), a not-for-profit genetics research institution and a repository for genetically engineered mice, today announced a joint agreement allowing JAX to distribute mouse models created using Sigma Life Science’s proprietary zinc finger nuclease (ZFN) technology.
Wednesday, 27 October 2010
Developing improved animal models of autism
Sigma Advanced Genetic Engineering (SAGE) Labs to use Proprietary Technologies to Create Genetically Engineered Rat Models to Better Understand Autism and Identify New Therapeutic Approaches
Sigma Life Science, the biological products and services research business of Sigma-Aldrich, today announced a partnership between its SAGE Labs division and Autism Speaks to create genetically engineered knockout rats to aid identification of new therapeutic approaches for the treatment of autism.
Sigma Life Science, the biological products and services research business of Sigma-Aldrich, today announced a partnership between its SAGE Labs division and Autism Speaks to create genetically engineered knockout rats to aid identification of new therapeutic approaches for the treatment of autism.
Tuesday, 14 September 2010
Three-year contract to supply Oligonucleotides
Sigma Life Science, a division of Sigma-Aldrich Corporation and a European manufacturer of oligonucleotides, has signed a three-year contract with Research Councils UK (RCUK) Shared Services Centre Limited to be a prefered supplier for synthetic oligonucleotides.
Sigma Life Science offers a broad commercially available range of high quality oligonucleotide modifications, purifications, synthesis scales and qPCR probes.
Sigma Life Science offers a broad commercially available range of high quality oligonucleotide modifications, purifications, synthesis scales and qPCR probes.
Thursday, 2 September 2010
Joint project to develop microRNA target validation system
Combining SwitchGear Genomics’ expertise with Sigma’s lentiviral technology, these ready-to-use reporter vectors are expected to simplify miRNA target validation, enabling researchers to investigate gene regulation in a variety of biological pathways.
Subscribe to:
Posts (Atom)